journal article·2017-11-17

Development and characterization of morin hydrate loaded microemulsion for the management of Alzheimer’s disease

Dheeraj Sharma, Manpreet Singh, Punnet Kumar, Vir Vikram, Neeraj Mishra

Publisher page

Abstract

The aim of this study is to prepare and characterize intranasal delivery of morin hydrate loaded microemulsion for the management of Alzheimer's diseases. After intranasal delivery, brain and blood drug concentrations were found to be higher for optimized morin hydrate loaded microemulsion as compared to plain morin hydrate. Significant (P < 0.05) reduction in assessed pharmacodynamic parameters was observed after intranasal administration of morin hydrate loaded microemulsion as compared to sham control group. Daily chronic treatment with morin loaded microemulsion till the 21st day significantly increased the memory in wistar rats with STZ-induced dementia.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Cholinesterase and Neurodegenerative Diseases · Advancements in Transdermal Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, I.S.F. College of Pharmacy, Moga, India;

Department of Pharmacology, I.S.F. College of Pharmacy, Moga, India;

Head, Pharmacy, DMCH, Ludhiana, India

References (28)

Show source-provided references
1. 10.1016/j.colsurfb.2014.11.02210.1016/j.colsurfb.2014.11.022 ↗
2. 10.1016/S0301-0082(02)00079-510.1016/S0301-0082(02)00079-5 ↗
3. 10.1016/j.ijpharm.2011.12.02810.1016/j.ijpharm.2011.12.028 ↗
4. 10.1016/j.pbb.2006.08.00710.1016/j.pbb.2006.08.007 ↗
5. 10.1016/j.ejphar.2009.08.02710.1016/j.ejphar.2009.08.027 ↗
6. 10.1016/j.tibs.2004.08.00110.1016/j.tibs.2004.08.001 ↗
7. 10.1016/0006-2952(61)90145-910.1016/0006-2952(61)90145-9 ↗
8. 10.1016/0003-9861(59)90090-610.1016/0003-9861(59)90090-6 ↗
9. 10.1016/j.ejpb.2014.03.00410.1016/j.ejpb.2014.03.004 ↗
10. 10.1016/j.nbd.2009.07.02810.1016/j.nbd.2009.07.028 ↗
11. 10.3109/1547691X.2016.115926410.3109/1547691X.2016.1159264 ↗
12. 10.1016/j.phrs.2003.11.01710.1016/j.phrs.2003.11.017 ↗
13. 10.1016/j.nbd.2011.07.00510.1016/j.nbd.2011.07.005 ↗
14. 10.1016/0003-2697(82)90118-X10.1016/0003-2697(82)90118-X ↗
15. 10.5530/jyp.2015.3.910.5530/jyp.2015.3.9 ↗
16. Moghimipour E · Adv Pharm Bull · 2013 · 3 · 63
17. 10.1016/j.bfopcu.2013.07.00210.1016/j.bfopcu.2013.07.002 ↗
18. 10.1016/j.apsb.2014.02.00210.1016/j.apsb.2014.02.002 ↗
19. 10.1016/j.bbr.2008.10.02910.1016/j.bbr.2008.10.029 ↗
20. 10.1166/asl.2010.114910.1166/asl.2010.1149 ↗
21. Sharma D · Asian J Biomater Res · 2016 · 2 · 1
22. 10.1016/j.ejpb.2015.08.00810.1016/j.ejpb.2015.08.008 ↗
23. 10.2174/15734131179448028210.2174/157341311794480282 ↗
24. 10.1016/j.jconrel.2010.08.00410.1016/j.jconrel.2010.08.004 ↗
25. 10.2174/18722110878624167910.2174/187221108786241679 ↗
26. 10.1002/jps.2048010.1002/jps.20480 ↗
27. 10.1042/bj099066710.1042/bj0990667 ↗
28. Zhang J · Int J Nanomedicine · 2011 · 6 · 3405